Glycemic control after initiating basal insulin therapy in patients with type 2 diabetes: a primary care database analysis

Código QR

Glycemic control after initiating basal insulin therapy in patients with type 2 diabetes: a primary care database analysis

Karel Kostev,1 Franz W Dippel,2 Wolfgang Rathmann3 1IMS Health, Frankfurt, 2Sanofi-Aventis Deutschland GmbH, Berlin, 3Institute of Biometrics and Epidemiology, German Diabetes Center, Düsseldorf, Germany Background: When target glycated hemoglobin (HbA1C) levels are not reached, basal insu...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kostev K, Dippel FW, Rathmann W
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/d96a65697f744995b869d645dbf1f710
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Fracture risk in patients with type 2 diabetes under different antidiabetic treatment regimens: a retrospective database analysis in primary care
por: Pscherer S, et al.
Publicado: (2016)

Insulin initiation and intensification in patients with T2DM for the primary care physician
por: Unger J
Publicado: (2011)

Changes in HbA1c, body weight, and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy: a primary care database study
por: Scheerer MF, et al.
Publicado: (2016)

Two-way crossover comparison of insulin glargine and insulin detemir in basal-bolus therapy using continuous glucose monitoring
por: Abe S, et al.
Publicado: (2011)

Critical appraisal of the safety and efficacy of insulin detemir in glycemic control and cardiovascular risk management in diabetics
por: Jean-Pierre Le Floch
Publicado: (2010)

Glucagon-like peptide-1 receptor agonists as add-on therapy to basal insulin in patients with type 2 diabetes: a systematic review
por: Berlie H, et al.
Publicado: (2012)

Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review
por: Wang F, et al.
Publicado: (2012)

Basal Insulin Initiation and Maintenance in Adults with Type 2 Diabetes Mellitus in the United States
por: Kalirai S, et al.
Publicado: (2020)

Withdrawal of sulfonylureas from patients with type 2 diabetes receiving long-term sulfonylurea and insulin combination therapy results in deterioration of glycemic control: a randomized controlled trial
por: Srivanichakorn W, et al.
Publicado: (2015)

Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus
por: Lau IT, et al.
Publicado: (2017)

The role of insulin glulisine to improve glycemic control in children with diabetes mellitus
por: Carter J, et al.
Publicado: (2010)

Challenges and unmet needs in basal insulin therapy: lessons from the Asian experience
por: Chan WB, et al.
Publicado: (2017)

Assessing the impact of a new delivery method of insulin on glycemic control using a novel trial design
por: Thomas Strack, et al.
Publicado: (2009)

The barriers against initiating insulin therapy among patients with diabetes living in Yazd, Iran
por: Shafie Pour MR, et al.
Publicado: (2019)

Glycemic control and anti-osteopathic effect of propolis in diabetic rats
por: Al-Hariri M,&nbsp;Gamal Eldin T, et al.
Publicado: (2011)

Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries
por: Ostenson CG, et al.
Publicado: (2013)

Real-world insulin therapy in German type 2 diabetes mellitus patients: patient characteristics, treatment patterns, and insulin dosage [Corrigendum]
por: Wilke T, et al.
Publicado: (2019)

Sotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes
por: Powell DR, et al.
Publicado: (2015)

Effects of zinc and multimineral vitamin supplementation on glycemic and lipid control in adult diabetes
por: Priyanka Gunasekara, et al.
Publicado: (2011)

Insulin glulisine in the management of diabetes
por: Satoru Yamada
Publicado: (2009)

Comorbidity and glycemia control among patients with type 2 diabetes in primary care
por: Catherine Hudon, et al.
Publicado: (2008)

HbA1c for diagnosis of type 2 diabetes. Is there an optimal cut point to assess high risk of diabetes complications, and how well does the 6.5% cutoff perform?
por: Kowall B, et al.
Publicado: (2013)

Effect of Adding Insulin Glargine on Glycemic Control in Critically Ill Patients Admitted to Intensive Care Units: A Prospective Randomized Controlled Study
por: Nader ND, et al.
Publicado: (2020)

Real-world glycemic outcomes in patients with type 2 diabetes initiating exenatide once weekly and liraglutide once daily: a retrospective cohort study
por: Saunders WB, et al.
Publicado: (2016)

Critical appraisal of the safety and efficacy of insulin detemir in glycemic control and cardiovascular risk management in diabetics
por: Le Floch J
Publicado: (2010)

Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update
por: Robert G Moses
Publicado: (2010)

The presence of diabetes impacts liver fibrosis and steatosis by transient elastography in a primary care population
por: Qunying Yang, et al.
Publicado: (2021)

Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes
por: Michael A Via, et al.
Publicado: (2010)

Pilot study on the additive effects of berberine and oral type 2 diabetes agents for patients with suboptimal glycemic control
por: Di Pierro F, et al.
Publicado: (2012)

Leukocyte peroxidase and leptin: an associated link of glycemic tolerance and bronchial asthma?
por: Sergio Parco
Publicado: (2010)

Reply to: The presence of diabetes impacts liver fibrosis and steatosis by transient elastography in a primary care population
por: Hirsh D. Trivedi, et al.
Publicado: (2021)

Myocardial perfusion imaging for evaluation of suspected ischemia and its relationship with glycemic control in South African subjects with diabetes mellitus
por: Shmendi A, et al.
Publicado: (2014)

Akt/PKB activation and insulin signaling: a novel insulin signaling pathway in the treatment of type 2 diabetes
por: Mackenzie RWA, et al.
Publicado: (2014)

Cumulative clinical experience with use of insulin lispro: critical appraisal, role in therapy, and patient considerations
por: Uy J, et al.
Publicado: (2012)

Insulin detemir for the treatment of obese patients with type 2 diabetes
por: Hollander PA
Publicado: (2012)

Relationship between oxidized low-density lipoprotein antibodies and obesity in different glycemic situations
por: Babakr AT, et al.
Publicado: (2014)

Level of sustained glycemic control and associated factors among patients with diabetes mellitus in Ethiopia: a hospital-based cross-sectional study
por: Abebe SM, et al.
Publicado: (2015)

An exploratory retrospective assessment of a quantitative measure of diabetes risk: medical management and patient impact in a primary care setting
por: Courtney MR, et al.
Publicado: (2015)

Potential glycemic overtreatment in patients ≥75 years with type 2 diabetes mellitus and renal disease: experience from the observational OREDIA study
por: Penfornis A, et al.
Publicado: (2015)

Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years
por: MacConell L, et al.
Publicado: (2013)